Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Thorac Dis ; 8(5): 920-4, 2016 May.
Article in English | MEDLINE | ID: mdl-27162667

ABSTRACT

BACKGROUND: Myocardial injury after non-cardiac surgery (MINS) is defined as troponin elevation of ≥0.03 ng/mL associated with 3.87-fold increase in early mortality. We sought to determine the impact of cardiology intervention on mortality in patients who developed MINS after general thoracic surgery. METHODS: A retrospective review was performed in patients over 5 years. Troponin was routinely measured and levels ≥0.04 ng/mL classified as positive. Data acquisition and mortality status was obtained via medical records and NHS tracing systems. Thirty-day mortality was compared on MINS cohort using Fisher's exact square testing and logistic regression analysis. RESULTS: Troponin levels were measured in 491 (96%) of 511 patients. Eighty (16%) patients fulfilled the MINS criteria. Sixty-one (76%) received early cardiology consult and "myocardial infarction" stated in four (5%) patients. Risk assessment (for AMI) was undertaken; 20 (25%) patients were commenced on aspirin, four (5%) on ß-blockers and one (1%) underwent percutaneous coronary intervention. Forty-nine (61%) patients received primary risk factor modifications and 26 (33%) had outpatient follow-up. There were no significant differences in the proportion of patients who died within 30 days post-operatively in the MINS group of 2.6% compared to the non-MINS group of 1.6% (P=0.625). The odds ratio for 30-day mortality in the MINS group was 1.69 (95% CI: 0.34 to 8.57, P=0.522). CONCLUSIONS: MINS is common after general thoracic surgery. Early cardiology intervention reduced the expected hazard ratio of early death from 3.87 to an odds ratio of 1.69 with no significant difference in 30-day mortality for patients who developed MINS.

2.
Thorax ; 70(4): 379-81, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25124060

ABSTRACT

Positron emission tomography-CT (PET-CT) is one of the initial mediastinal staging modality for non-small cell lung cancer; however, the clinical utility in carcinoid tumours is uncertain. We sought to determine the test performance of PET-CT for mediastinal lymph node staging of pulmonary carcinoid tumours. We collated data from seven institutions, performing a retrospective search on pathological databases for a consecutive series of patients who underwent thoracic surgery (with lymph nodal dissection) for carcinoid tumours with preoperative PET-CT staging. PET-CT results were compared with the reference standard of pathologic results obtained from lymph node dissection and test performance reported using sensitivity and specificity. From November 1999 to January 2013, 247 patients from seven institutions underwent surgery for carcinoid tumours with a corresponding preoperative PET-CT scan. The mean age of the patients was 61 (SD 15, range 73) and 84 were male patients (34%). The pathologic subtype was typical carcinoid in 217 patients (88%) and atypical carcinoid in 30 patients (12%). Results from lymph node dissection were obtained in 207 patients. The calculated sensitivity and specificity of PET-CT to identify mediastinal lymph node disease was 33% (95% CI 4% to 78%) and 94% (95% CI 89% to 97%), respectively. Our results indicate that PET-CT has a poor sensitivity but good specificity to detect the presence of mediastinal lymph node metastases in pulmonary carcinoid tumours. Mediastinal lymph node metastases cannot be ruled out with negative PET-CT uptake, and if the absence of mediastinal lymph node disease is a prerequisite for directing management, tissue sampling should be undertaken.


Subject(s)
Carcinoid Tumor/pathology , Lung Neoplasms/pathology , Aged , Carcinoid Tumor/diagnostic imaging , Carcinoid Tumor/secondary , Female , Fluorodeoxyglucose F18 , Humans , Lung Neoplasms/diagnostic imaging , Lymphatic Metastasis , Male , Mediastinum , Middle Aged , Multimodal Imaging/methods , Neoplasm Staging , Positron-Emission Tomography/methods , Radiopharmaceuticals , Sensitivity and Specificity , Tomography, X-Ray Computed/methods
4.
J Thorac Oncol ; 8(1): 37-44, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23242436

ABSTRACT

INTRODUCTION: Currently, no agreed histologic grading system exists for lung adenocarcinomas (ADCs). With a recently updated consensus classification, the aim of this study was to assess potential prognostic factors identifiable on routine histology, which might be used as grading parameters. METHODS: A retrospective study of resected pulmonary ADCs (n = 238) in patients with stage IA to IIIB disease was carried out in which various histopathological parameters were correlated with survival data. The relationship between these factors and patient survivability was analyzed using Cox proportional hazards regression. RESULTS: Mitotic rate was found to be a highly significant prognostic marker (p = 0.008), as was overall nuclear grade (p < 0.001). ADC subtyping was also found to be potentially important, as lepidic predominant (hazard ratio 0.99, p = 0.023) and solid predominant (hazard ratio 1.01, p = 0.003) subtypes were found to be independent (to age and tumor, node, metastasis category) prognostic predictors. Vessel invasion within tumor approached significance as a negative prognostic factor (p = 0.067). CONCLUSIONS: This study showed not only that histologic subtype and mitotic rate are important prognostic factors in lung ADCs, but also that other criteria described previously may not be useful in our specific patient population.


Subject(s)
Adenocarcinoma/pathology , Lung Neoplasms/pathology , Mitotic Index , Adenocarcinoma/surgery , Adult , Aged , Aged, 80 and over , Blood Vessels/pathology , Female , Humans , Lung Neoplasms/surgery , Male , Middle Aged , Neoplasm Grading , Neoplasm Invasiveness , Neoplasm Staging , Prognosis , Proportional Hazards Models , Retrospective Studies
5.
J Travel Med ; 19(4): 250-2, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22776387

ABSTRACT

High altitude commercial expeditions are increasingly popular. As high altitude illnesses are common on ascent to altitude, this study aimed to ascertain whether medications for these conditions were carried by commercial operators who run high altitude expeditions. Despite recommendations, it appears that drugs to treat high altitude illnesses are not routinely carried by commercial operators.


Subject(s)
Altitude Sickness/drug therapy , Equipment and Supplies/standards , Mountaineering , Altitude , Emergency Medicine/instrumentation , Expeditions , Humans , United Kingdom
SELECTION OF CITATIONS
SEARCH DETAIL
...